Labeling technique during noninvasive tumor imaging could predict response to chemotherapy

July 16, 2014
Improved imaging techniques for tumor blood vessel networks will help improve the targeting of intravenous chemotherapy. Credit: BluePlanetEarth/iStock/Thinkstock

Being able to view tumor blood vessels without surgery or potent dyes can improve our understanding of the environment in which a tumor grows. Now, a team of researchers, including Chang-Tong Yang from the A*STAR Singapore Bioimaging Consortium, have developed a contrast agent that selectively labels the tumor blood vessel network for use in noninvasive tumor imaging studies.

Assessing the extent of the blood vessel network within a enables doctors to determine how far along the cancer has progressed and to predict whether a tumor will respond to intravenous chemotherapy drugs through modeling the drug's potential path and absorbance. While noninvasive imaging techniques can help visualize all blood vessels in patients, visualizing the blood vessels of a tumor requires a contrast agent that can selectively label the . Such substances concentrate within tumors by binding to molecules that are more prevalent in tumors than in normal tissues.

The researchers developed a contrast agent called Gd(DO3A-Lys) that has an optimal half-life, meaning it persists in the blood long enough to be useful as an imaging aid. Contrast agents that strongly bind blood albumin increase the visibility of large blood vessels and are already in clinical use, explains research co-leader Edward George Robins. However, Gd(DO3A-Lys) only weakly binds albumin, enabling the contrast agent to specifically target and visualize areas that contain tumors and their microvasculature.

Contrast agents eventually leave the body when filtered through the kidneys. Promisingly, the researchers were able to show that Gd(DO3A-Lys) has low toxicity to kidney cells growing in culture. In addition, mice given a single dose of Gd(DO3A-Lys) showed no kidney toxicity at both low and high doses, although the high-dose treatment did result in some damage to the liver—the organ responsible for breaking down drugs.

After administering Gd(DO3A-Lys) to tumor-bearing mice, Yang and colleagues used contrast-enhanced magnetic resonance imaging (CE-MRI) to demonstrate that the contrast agent selectively localized to the site of the tumor. Importantly, as only a minimal amount leaked from the into the tumor itself, Gd(DO3A-Lys) appeared to be retained within the tumor's blood vessel network, allowing the fine structures of the tumor vessels to be clearly imaged.

While the team's results are encouraging, clinical use of Gd(DO3A-Lys) is still a long way off. Further study is needed to assess the sensitivity of Gd(DO3A-Lys) to detect changes in the tumor vasculature and potential interactions with tumor treatments such as anti-angiogenesis drugs.

Explore further: Noninvasive measurement enables use of IFP as potential biomarker for tumor aggressiveness

More information: Yang, C.-T., Chandrasekharan, P., He, T., Poh, Z., Raju, A., Chuang, K.-H., & Robins, E. G. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography. Biomaterials 35, 327–336 (2014). dx.doi.org/10.1016/j.biomaterials.2013.10.006

Related Stories

Noninvasive measurement enables use of IFP as potential biomarker for tumor aggressiveness

October 1, 2012
Researchers validated a method of noninvasive imaging that provides valuable information about interstitial fluid pressure of solid tumors and may aid in the identification of aggressive tumors, according to the results of ...

Improved ultrasound imaging provides alternate way to visualize tumors

January 29, 2014
While ultrasound provides a less expensive and radiation-free alternative to detecting and monitoring cancer compared to technologies such as X-rays, CT scans, and MRIs, ultrasound has seen limited use in cancer treatment ...

Brain tumor invasion along blood vessels may lead to new cancer treatments

July 8, 2014
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, a study in mice indicates. This finding could ultimately lead to new ways ...

Starving pancreatic cancer before it has a chance to feast

June 23, 2014
(Medical Xpress)—Pancreatic cancer's low survival rate gives researchers from The University of Kansas Cancer Center even more reason to find a way to prevent and treat the hard-to-detect cancer. Drs. Snigdha Banerjee, ...

Nano drug crosses blood-brain tumor barrier, targets brain tumor cells and blood vessels

July 17, 2013
(Phys.org) —An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a recent study led ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.